TURNOVER (x1000 NOK)
NET PROFIT (x1000 NOK)
EMPLOYEES
Bergentoft Pharma Consulting AB
Closing information (x1000 NOK)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
2,010
|
1,943 | |
| Financial expenses |
8
|
0 | |
| Earnings before taxes |
1,757
|
1,198 | |
| EBITDA |
1,740
|
1,198 | |
| Total assets |
4,031
|
2,779 | |
| Current assets |
3,063
|
1,833 | |
| Current liabilities |
634
|
725 | |
| Equity capital |
3,143
|
1,909 | |
| - share capital |
51
|
47 | |
| Employees (average) |
1
|
2
|
1 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
78.0%
|
68.7% | |
| Turnover per employee |
1,005
|
1,943 | |
| Profit as a percentage of turnover |
87.4%
|
61.7% | |
| Return on assets (ROA) |
43.8%
|
43.1% | |
| Current ratio |
483.1%
|
252.8% | |
| Return on equity (ROE) |
55.9%
|
62.8% | |
| Change turnover |
-71
|
831 | |
| Change turnover % |
-100%
|
-3%
|
75% |
| Chg. No. of employees |
-1
|
1
|
0 |
| Chg. No. of employees % |
-50%
|
100%
|
0% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.